The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
E. Hausmann
No relevant relationships to disclose
W. Glienke
No relevant relationships to disclose
L. Bergmann
No relevant relationships to disclose